Hormonal Therapy · FDA-approved (multiple forms) · Prescription required
Testosterone Replacement Therapy (TRT)
TRT restores testosterone to normal levels in men with clinically confirmed hypogonadism (low testosterone). A landmark 2023 clinical trial finally settled a decade-long question about cardiovascular safety — with results that are genuinely reassuring, and a few honest caveats worth understanding before starting.
Overview
What TRT actually treats
TRT is intended for men with clinically diagnosed hypogonadism — confirmed low testosterone levels accompanied by symptoms such as low libido, fatigue, reduced muscle mass, or mood changes. Diagnosis typically requires two separate fasting morning testosterone measurements below the normal reference range, alongside consistent symptoms, per Endocrine Society clinical practice guidelines.
It is not intended as a general anti-aging or bodybuilding treatment for men with normal testosterone levels — appropriate use depends on an actual diagnosis, not simply wanting higher levels.
Testosterone is a DEA Schedule III controlled substance in the United States, requiring a valid prescription from a licensed provider. Testosterone obtained outside a legitimate prescribing relationship — including from underground or gray-market sources — is illegal and carries real purity, sterility, and legal risks.
The trial that changed the conversation
TRAVERSE (2023) — what it actually found
For years, conflicting small studies left real uncertainty about whether TRT increased cardiovascular risk — serious enough that the FDA required testosterone manufacturers to fund a definitive trial in 2015. That trial, TRAVERSE, published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45–80 with confirmed hypogonadism and existing or high cardiovascular risk — the largest, most rigorous study of its kind.
No increase in major cardiovascular events
Testosterone therapy was noninferior to placebo for the primary composite endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke. There was also no increase in prostate cancer or prostate-related events — directly addressing two of the most common patient concerns about TRT.
Some unexpected risks did appear
The trial found more cases of nonfatal arrhythmias requiring intervention, atrial fibrillation, and acute kidney injury in the testosterone group compared to placebo — findings the investigators themselves said were “not expected.” These are real signals worth discussing with your provider, even though the primary safety question was reassuring.
Delivery methods
Injections, gels, and pellets compared
One detail worth knowing before choosing a delivery method: not all pellet products are FDA-approved. Testopel® is the FDA-approved pellet formulation; many clinics use compounded pellet alternatives that are not FDA-approved and lack the same regulatory oversight. Ask your provider directly which product they use.
| Method | Frequency | FDA-approved options | Considerations |
|---|---|---|---|
| Injectable (cypionate, enanthate) | Weekly to biweekly | Yes — multiple brands | Level fluctuations between doses; most affordable option generally |
| Transdermal gel | Daily | Yes (e.g., AndroGel®) | Risk of transfer to others via skin contact; steadier levels than injections |
| Subcutaneous autoinjector | Weekly | Yes (Xyosted®) | Self-administered; steady dosing |
| Pellet (Testopel®) | Every 3–6 months | Yes — this specific product | Minor in-office insertion procedure; long-acting convenience |
| Compounded pellets (non-Testopel®) | Every 3–6 months | No — not FDA-approved | Lacks FDA oversight of dosing consistency and manufacturing standards |
| Oral (undecanoate) | Twice daily with food | Yes (Jatenzo®) | Must be taken with fat-containing meal for absorption |
Testosterone Injections
Cypionate vs. enanthate, and the real study showing subcutaneous injection produces meaningfully lower hematocrit and estradiol than intramuscular.
Testosterone Gel
Real absorption data and the FDA’s own transfer study — what happens with unprotected skin contact, and how to prevent it.
Testosterone Cream
Why no cream product is FDA-approved, real bioequivalence data vs. gel, and the same documented transfer risk.
Pellet Testosterone Therapy
Testopel® vs. compounded pellets — a real trial comparing both, plus real extrusion and infection rate data.
What responsible monitoring looks like
Why regular bloodwork matters throughout treatment
Given the TRAVERSE trial’s findings, hematocrit (red blood cell concentration) monitoring is particularly important, since elevated hematocrit is a known risk with testosterone therapy and can affect cardiovascular risk. Responsible TRT management includes baseline labs before starting, follow-up testosterone and hematocrit checks within the first few months, and ongoing monitoring — along with periodic prostate-specific antigen (PSA) checks per your provider’s guidance.
Common questions
Frequently asked questions
Does TRT increase heart attack or stroke risk?
The largest, most rigorous trial to date (TRAVERSE, 2023, n=5,246) found testosterone therapy was not associated with an increase in major cardiovascular events compared to placebo. However, the same trial found more cases of arrhythmia, atrial fibrillation, and acute kidney injury in the testosterone group — real findings worth discussing with your provider, even though the primary safety question was reassuring.
Does TRT increase prostate cancer risk?
The TRAVERSE trial found no increase in prostate cancer or prostate-related events in the testosterone group compared to placebo — directly addressing a common historical concern about TRT and prostate health.
Are all testosterone pellets FDA-approved?
No. Testopel® is the FDA-approved pellet formulation. Many clinics use compounded pellet products that are not FDA-approved and don’t carry the same manufacturing and dosing oversight. Ask your provider specifically which product they use.
Can I get TRT if my testosterone is normal but I want higher levels?
TRT is intended to treat diagnosed hypogonadism — confirmed low testosterone with accompanying symptoms — not to boost normal levels further. A responsible provider will require actual diagnostic bloodwork before prescribing, consistent with Endocrine Society guidelines.
Find a TRT provider
Search our directory of vetted physicians offering testosterone replacement therapy — or ask in the forum to hear from men who have been through it.
Key sources: Lincoff et al., “Cardiovascular Safety of Testosterone-Replacement Therapy,” New England Journal of Medicine (2023) · Bhasin et al., “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline,” JCEM (2018)
This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Testosterone is a Schedule III controlled substance requiring a valid prescription. Always consult a licensed physician before pursuing any treatment. PhallusMD does not endorse specific providers or products.
There are no reviews yet. Be the first one to write one.